International Regulators Explain Work-Sharing Scheme For Biosimilars
Follows Pilot Launched Earlier This Year
Executive Summary
New guidance from the ACCESS Consortium of regulators from five countries explains how biosimilar drug sponsors can apply for an internationally-coordinated review of new products.
You may also be interested in...
International Regulator Consortium Eyes Real-World Data
The five-member ACCESS Consortium has outlined how it intends to build on its work-sharing experiences by applying innovative regulatory practices to the assessment of increasingly complex medicinal products.
Brexit: MHRA Joins Second International Work-Sharing Scheme To Speed Up Drug Approvals
Hot on the heels of announcing it was joining Project Orbis, the UK drug regulator, the MHRA, now says it will join another international collaboration that allows drug companies to submit medicines for review by several countries at the same time.
Hat Trick For Xofluza As Canadian, Swiss & Australian Regulators Join Forces
Xofluza is also the first non-cancer drug to be reviewed under the Australia-Canada-Singapore-Switzerland (ACSS) Consortium’s work-sharing initiative.